Carestream submits OnSight 3D Extremity System for FDA clearance

Carestream Health has announced the filing of a 510(k) application with the FDA for clearance of its OnSight 3D Extremity System, according to a company press release.

The system, which uses cone beam CT technology to capture images of patient extremities, is designed to offer affordable yet high-quality low-dose 3D imaging.

“Orthopaedic imaging is a major focus for Carestream because of the prevalence of musculoskeletal conditions among people of all ages,” said Helen Titus, a marketing director with the Rochester, N.Y.-based healthcare company. “Our goal is to offer a compact, affordable imaging system that enables a variety of healthcare providers to produce extremely high-quality 3D images of extremities including weight-bearing exams.”

The OnSight 3D Extremity System is designed for use by orthopaedic and sports medicine practices, hospitals, imaging centers, urgent care facilities and other healthcare providers, and is currently being tested in trials and research studies in the United States and Europe.

 

John Hocter,

Digital Editor

With nearly a decade of experience in print and digital publishing, John serves as Content Marketing Manager. His professional skill set includes feature writing, content marketing and social media strategy. A graduate of The Ohio State University, John enjoys spending time with his wife and daughter, along with a number of surprisingly mischievous indoor cacti.

Around the web

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.